Are you a former employee of LogicBio Therapeutics, Inc. (LOGC) and own stock in the company? Robbins LLP is investigating breaches of fiduciary duty by the officers and board of directors of LOGC.

LogicBio Therapeutics, Inc. (LOGC) Accused of Misleading Shareholders 

On April 1, 2019, LogicBio Therapeutics, Inc. touted its progress with LB-001 stating "the Company continues to advance its lead product candidate to an expected Investigational New Drug (IND) by the end of 2019" and into a Phase 1/2 clinical trial in MMA patients in 2020. Then, on January 10, 2020, the Company announced the submission of its IND with the U.S. Food and Drug Administration (FDA).  Finally, on February 10, 2020, LogicBio revealed that "the has placed a clinical hold on the submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions." On this news, LogicBio's share price fell almost 32%, to close at $7.11 per share. The stock continues to decline.